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LETTER TO EDITOR

Predicting the early risk of ophthalmopathy in Graves’
disease patients using TCR repertoire
To the Editor:
At present, predicting the early risk of ophthalmopathy
in Graves’ disease patients is extremely difficult. In this
study, we proposed a novel score—TCR clonal expansion
and chaos score (TCS)—to characterize TCR V-J combination (VJ). And VJ signatures that could distinguish Graves’
ophthalmopathy (GO) from Graves’ hyperthyroidism (GH)
were used to successfully predict GO progression.
GH is an organ-specific autoimmune disease, with an
annual incidence of 20-50 cases per 100 000 persons.1 GO
characterized by disfiguring and dysfunctioning features
of corneal breakdown or optic neuropathy occurs in 3-5%
GH patients, which significantly decreases the quality of
life.1 Identification of signatures that prospectively predict
progression from GH to GO may open the possibility for
prophylactic intervention to prevent GO. Two studies have
reported that restricted usage of TCR may contribute to the
recruitment and oligoclonal expansion of T cells in early
stage of GO.2,3 As GO is autoimmune-mediated inflammation and TCR repertoires snapshot current accumulated
adaptive immune events, we reasoned that specific TCR
signatures emerging before ophthalmopathy presentation
might be appropriate predictors for GO progression.
It was reported that T cells showing clonal expansion in
tissues such as kidney or tumors can be traced in blood,
enabling monitor of disease progression.4,5 In this study,
we first compared T-cell repertoires between thyroids and
blood from six GH patients, and confirmed that the majority of expanded clonotypes (with frequencies over 0.001)
in thyroids could be detected in blood (Figure 1A,B).
Based on similarity index,6 top 20 T-cell clonotypes correlated better within thyroids and blood than top 21-1000
T-cell clonotypes (Figure 1C). These results indicated that
blood-derived T-cell repertoires may reflect tissue-specific
immune response and facilitate disease surveillance.
To further characterize specific TCR signatures, we
sequenced the RNA transcripts from the complementarity determining region 3 (CDR3) of TCR Vβ from 100
peripheral blood samples, including 43 GO and 57 sta-

ble GH (Table S1). Stable GH was defined as no GO
progression within 18 months follow up.1 All nucleotide
sequences were aligned to reference TCR Vβ/Dβ/Jβ gene
segments (Figure S1), and the number of reads generated
was 16.277 ± 6.732 million from each sample (Table S1).
Previous studies on TCR mainly focused on the highly
expanded clonotypes.7 Here, we represented clonal expansion by F50, which was defined as the frequency of a CDR3
sequence whose cumulative percentage reached 50% in
descending-ordered VJ (Figure 2A-C, Figure S2, Equation S1 in the Supporting Information). And F50, rather
than the total frequency could precisely depict the clonal
expansion status in VJs among individuals (Figure 2AC). For instance, TRBV27-TRBJ1-5 and TRBV28-TRBJ2-7
were with parallel frequency of 0.063 and 0.067 in sample YL2713 and WL1046, respectively. However, their distribution of cumulative frequency differed dramatically.
Specifically, there is a significant oligoclonal expansion
in TRBV27-TRBJ1-5, whereas no such phenomenon is
observed in TRBV28-TRBJ2-7. And F50 in TRBV27-TRBJ15 and TRBV28-TRBJ2-7 were 0.057 and 8.60E-06, respectively (Figure 2B,C).
Apart from clonal expansion, it also has been suggested
that the homology of CDR3 sequence plays a vital role in
antigen specificity.8 To describe chaos of CDR3 sequence
similarity, we first constructed a TCRdist matrix by measuring weighted Hamming distances of every two CDR3
sequence in VJ.8 And then entropy-variability (E-V) scores
of TCRdist matrix were applied to quantify the chaos of
CDR3 sequence similarity.9,10 E and V represented the
Shannon entropy and the number of different distances
observed in TCRdist matrix, respectively (Figure 2D, Figure S3, Equation S2 in the Supporting Information).
It is known that T-cell clonal expansion occurs when
antigen-driven activated and CDR3 sequence recognizing
the same pMHC epitope often share conserved sequence
features.8 Thus, we argued that when T cells are activated
by specific antigens, the F50 of specific VJ would increase,
and/or its corresponding chaos would decrease. Thereby,
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F I G U R E 1 T cells showing clonal
expansion in thyroids can be detected in
blood. A, Overlap of T-cell clonotypes
between thyroids and blood in six GH
patients. The numbers of unique clonotypes
in thyroids and blood are shown in the Venn
diagram. B, Cumulative frequency
distribution of T-cell clonotypes in thyroid
(y-axis) with frequencies below or over 0.001
(x-axis). Orange bar represents the
percentage of overlapped clonotypes
between thyroids and blood, blue bar
represents the percentage of thyroid-specific
clonotypes, and the number in the bar
indicated the clonotype counts. For sample
WL0465, in group of below 0.001, the
percentage of overlapped clonotypes (6055)
was 54.11%, and the thyroid-specific
clonotypes (15 159) was 23.55%. Whereas, in
group of over 0.001, all clonotypes (120) were
overlapped, and the percentage was 22.34%.
C, Comparison of Morisita-Horn (MH)
similarity index between thyroids and blood
at both directions in three groups including
“all clonotypes,” “top 20 clonotypes,” and
“top 21-1000 clonotypes.” The orange and
blue bars represent MH similarity scores of
blood in thyroid and thyroid in blood in six
GH patients, respectively. The range of MH
similarity score is from 0 (no similarity) to 1
(absolute similarity). Error bars represent
the standard deviation of MH similarity
scores in each sample group. Independent
two-tailed t-tests were performed to compare
MH similarity scores

we proposed a novel score termed TCR clonal expansion
and chaos score (TCS) as the ratio between F50 and chaos
to characterize VJ (Figure S4, and Equation S3 in the Supporting Information).
We computed the TCS values of 100 samples (Supporting Information File S1), and selected candidate features
with the best performance of classification from a train-

ing set of 33 GO and 37 stable GH (Figure S5a,b). Briefly,
‘Welch’s t-statistics method was used for shrinking the
number of features from 514 to 75 VJs, and random forest (v4.6-14, ntree = 1000) method was further applied
to reduce the number to 13 VJs (Supporting Information
File S2, Figure S5c). A diagnostic model was constructed
based on the selected 13 VJs using naïve Bayes (R package,
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F I G U R E 2 Characterization of the clonal expansion and CDR3 sequence similarity in TCR VJ combinations. A, Schematic diagram of VJ
and the corresponding CDR3 sequences in individual samples. Variable number of CDR3 sequence in VJs, and for each VJ, the CDR3 sequences
are heterogeneous. B, The usages of V and J genes in YL2713 and WL1046 samples are illustrated by Circos plots. The V and J genes are clockwise
arranged in the order of their frequencies from low to high. VJs are illustrated by colored curved paths whose thickness represents their total
frequencies in TCR repertoires. C, Example of the CDR3 sequence clonal expansion by Pareto chart on TRBV27-TRBJ1-5 and TRBV28-TRBJ2-7 in
sample YL2713 and WL1046. The frequency of CDR3 sequence is represented in a descending order by red bars, and the cumulative percentages
are represented by the blue point. The left and right y-axes are the frequency and cumulative percentage of CDR3 sequence, respectively. The
black dash line represents the F50, which was defined as the frequency of a CDR3 sequence whose cumulative frequency was 50% in VJ. In total,
there were 653 and 14360 CDR3 sequences in TRBV27-TRBJ1-5 and TRBV28-TRBJ2-7, respectively. D, Example of the CDR3 sequence similarity
in TRBV27-TRBJ1-5 and TRBV28-TRBJ2-7 in sample YL2713 and WL1046. t-SNE was applied on TCRdist matrix to indicate the similarities of
each CDR3 sequence pair. Each red dot represents a CDR3 sequence, and the size and color gradient indicate its frequency. Entropy-variability
(E-V) score of TCRdist matrix represents the chaos. In this example, the E-V score is 319.896 and 507.097 in TRBV27-TRBJ1-5 and TRBV28TRBJ2-7, respectively
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F I G U R E 3 VJ signatures with potential of distinguishing GO from GH is able to predict GO progression. A, Receiver operating characteristic curve (ROC) of the diagnostic model based on 13 selected VJ signatures in the training and test datasets. B and C, The hierarchical
clustering of 13 VJ signatures selected for use in the diagnostic model in the training and test datasets. D, Confusion table of binary results of 13
VJ signatures in prediction of GO progression in GH patients. E, GO-free survival curve shows the progression of GO in initial GH patients with
TCR prediction as GO or GH. F, Schematic diagram of disease progression from GH to GO. Transition from GH to GO involves a latency phase,
and TCR could be applied as prospective signatures for GO progression. Prophylaxis in latency phase may be applied based on prediction of
risk in GH patients

e1071: naïveBayes, v1.7-2) classifier. The leave-one-out
cross-validation showed a sensitivity of 87.88% and a
specificity of 81.08% to differentiate GO from stable GH
(AUC = 0.817, Figure 3A, Table S2). We subsequently tested
10 GO and 20 stable GH using our diagnostic model, which
achieved 80% sensitivity and 75% specificity to differentiate
GO from stable GH (AUC = 0.800, Figure 3A, Table S3).
To further confirm the selected features and incorporate

the internal difference between GO and GH, unsupervised
hierarchical clustering were performed on both training
and testing dataset (Figure 3B,C). The results indicated
that GO and GH can be distinguished clearly.
Next, we were curious about the predictive power of
TCR repertoires for GO progression. Our model was
applied in an independent validation study consisting of
18 GH samples and 17 “GH to GO” samples. “GH to GO”
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referred to initially diagnosed as GH but progressed to GO
by follow up. “GH to GO” were regarded as GO in this test,
and it achieved a sensitivity and specificity of 70.59% and
72.22% for prediction, respectively (Figure 3D). Specifically,
12 of the 17 “GH to GO” patients who were predicted as
GO developed symptoms of eyelid swelling, chemosis, or
proptosis within follow-up period, and were confirmed of
GO by computed tomography of the orbit in a median of
6.5 months (4-9.75 months IQR, Table S4). The patients in
the validation set were divided into two groups based on
the prediction type, and GO-free survival analysis was performed. The results demonstrated that “predicted as GO”
patients (n = 17) were significantly different from “predicted as GH” patients (n = 18) in GO progression (P = .015,
log-rank test; Figure 3E). These results suggested that transition from GH to GO involves a latency phase, and TCR
were prospective signatures for GO progression.
In summary, our study presented a novel score TCS
combining clonal expansion of VJ and chaos of CDR3
sequence similarity. And then we developed a model for
prediction of GO progression in a GH cohort as early as
a median of 6.5 months, with a sensitivity and specificity
of 70.59% and 72.22%, respectively. This finding suggests
that GO is characterized as a spectrum of autoimmunemediated inflammation states, and transition from GH to
GO involves a latent phase during which pathogenic TCR
evolves before ophthalmopathy presents (Figure 3F). Identification of complication risk in GH patients is unprecedented, and this may open the possibility for prophylactic
intervention to prevent GO. The novel approaches developed in this study may improve early detection and foster
prophylactic strategy in other autoimmune diseases.
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